Merck & Co., Inc. (MRK) News Today

Merck & Co., Inc. (NYSE: MRK) is trading higher as investors respond to renewed confidence in its oncology pipeline and broader business outlook. However, the stock’s sharp 2026 rally has also raised valuation concerns.

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine, supporting the company’s efforts to expand its oncology franchise beyond existing treatments. Merck Reports Promising Skin Cancer Trial Results
• Positive Sentiment: Investors are anticipating first-time pivotal Phase 3 oncology data at ESMO 2026, including melanoma and endometrial-cancer studies. Merck’s planned oncology investor event could provide additional detail on growth candidates intended to offset future pressure on established products. Merck ESMO 2026 Oncology Pipeline Preview
• Positive Sentiment: Merck’s sustained uptrend has prompted bullish options positioning, indicating that some traders expect further gains in the near term. Merck Stock Options Strategy
• Neutral Sentiment: Merck has gained more than 38% in 2026, and its forward earnings multiple has risen to about 15.3 from 8.6 in late 2025. The re-rating reflects improved sentiment, but also means stronger execution may already be priced in. Merck Rally and Valuation
• Negative Sentiment: At roughly 5.5 times sales, Merck trades at a premium to the S&P 500. Investors are increasingly focused on the company’s strategic shift and whether new growth drivers can overcome patent pressure and challenging Gardasil conditions in China. How Merck’s Story Has Changed